Updated: ContraFect to terminate PhIII MRSA antibiotic trial — stock capsizes

Lei Lei Wu

News Reporter

One year after BARDA backed ContraFect’s MRSA treatment, the Yonkers, NY-based biotech said Wednesday it will stop its Phase III trial of the asset early …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Updated: ContraFect to terminate PhIII MRSA antibiotic trial — stock capsizes

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Trump’s science crackdown hits rare disease research: ‘We need to sit down with Elon Musk’

At least seven drugmakers say they will participate in round two of IRA negotiations

Exclusive: Infectious disease doctors consider 'mini-ACIP' if RFK erodes CDC vaccine panel

Lilly joins molecular glue field with Magnet deal worth up to $1.25B

BridgeBio oncology spinout to go public via combination with SPAC from Cormorant and Bihua Chen

How AI can address ongoing challenges in the life sciences industry

Up­dat­ed: Con­tra­Fect to ter­mi­nate PhI­II MR­SA an­tibi­ot­ic tri­al — stock cap­sizes

News Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Updated: ContraFect to terminate PhIII MRSA antibiotic trial — stock capsizes